Evaluation of Accelerator-Based Boron Neutron Capture Therapy in Patients with Head and Neck Carcinoma

The primary objective of this study is to evaluate the efficacy of **accelerator-based boron neutron capture therapy (BNCT)** in the treatment of **head and neck carcinoma**. This is clinically relevant as head and neck carcinoma represents a group of aggressive malignancies with significant morbidity and mortality, and BNCT offers a targeted therapeutic approach that could potentially improve patient outcomes by selectively destroying cancer cells while sparing surrounding healthy tissue.

The clinical trial focuses on individuals diagnosed with **head and neck carcinoma**. The study population includes both male and female participants, with an age range spanning from 18 to 64 years. Participants are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the trial. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the efficacy of **accelerator-based BNCT** for the treatment of **head and neck carcinoma**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is November 1, 2024, with an anticipated completion date of December 1, 2029. Participants will be involved in the study for the duration of the trial, unless early termination is warranted due to specific conditions such as adverse events or withdrawal of consent.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, treatment adherence, and any adverse effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments are conducted to evaluate the overall outcomes and safety of the treatment.

Participants are expected to adhere to the study protocol for the entire duration of their involvement. Conditions that may lead to early termination from the study include significant protocol deviations, the occurrence of serious adverse events, or voluntary withdrawal by the participant. The trial aims to provide comprehensive data on the safety and efficacy of the treatment, contributing valuable insights into the management of head and neck carcinoma.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments, including their names, forms, dosages, or administration routes. Information on dosing schedules and participant compliance monitoring is also not available in the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on November 1, 2024, with an estimated completion date of December 1, 2029. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The schedule for measuring and collecting data will be aligned with the trial's timeline, ensuring that all necessary data points are captured for comprehensive analysis. The trial will utilize validated tools and instruments to ensure the reliability and validity of the efficacy assessments. The data collected will be analyzed to determine the treatment's impact on the specified medical condition, with results contributing to the overall evaluation of the treatment's efficacy.